Dr. John Cush RheumNow
3 years 3 months ago
Combination Cannabidiol (CBD) & hydroxychloroquine in RA? A phase II trial of IHL-675A (CBD+HCQ) will soon begin; following on phase I and animal studies showing it was tolerated, with no adverse events of concern.IHL-675A was superior to HCQ alone. https://t.co/H90D9LzNSo https://t.co/JiS6HL38Jg
Dr. John Cush RheumNow
3 years 3 months ago
RNase Treatment of Autoimmune Disorders
U1RNP complex, Ro/SSA and La/SSB are major RNA-containing autoantigens associated with autoimmune disorders.
https://t.co/4Q8NGgKvfj https://t.co/QavCtY1E83
Dr. John Cush RheumNow
3 years 3 months ago
Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/vGt12ul6iy https://t.co/044BScmSYc
Dr. John Cush RheumNow
3 years 3 months ago
US claims data shows the incidence rate of Herpes zoster (HZ) to be higher in RA (21.5/1000PY;HR 1.93) than non-RA (7.6/1000PY), increasing with age in RA,≥ 65 yrs -23.4/1000PY), highest w/ steroids and JAK inhibitors https://t.co/yH5bRGEyFh https://t.co/avvHwPkvJB
Dr. John Cush RheumNow
3 years 3 months ago
Bringing pivotal clinical trials to you: announcing RheumNow’s Poster Hall, featuring previously presented, sponsor-generated clinical trial posters designed to educate and inform.
https://t.co/dHg0rrKcQ8 https://t.co/qtUxGg3waX
Dr. John Cush RheumNow
3 years 3 months ago
Infectious Risk with B Cell Therapies in Lupus
A UK registry study of moderate to severe SLE showed that treatment with rituximab or belimumab was not associated with a greater risk of serious infection, when compared to standard of care therapy.
https://t.co/AbqrlU3qpw https://t.co/RlyWaTjWO1
Dr. John Cush RheumNow
3 years 3 months ago
Words of wisdom from Dr. Bharat Kumar, editor of the Rheumatologist @BharatKumarMD https://t.co/VbgI9ew5T8
Dr. John Cush RheumNow
3 years 3 months ago
Cohort comparison of Psoriatic arthritis in 141 males vs 131 females: found psoriasis (BMI , BSA) was worse in males, but PsA worse in females (higher PtGA, PtPnV, TJC, SJC, DAPSA, HAQ-DI, and PsAID-12). Men more likely to get to MDA than females https://t.co/e1mFo0kCtL https://t.co/LfJJZc5Ecp
The CDC estimates that nearly 220,000 children and adolescents had arthritis during 2017–2021. Prevalence (305 per 100,000) increased with age and is higher in 12–17 year olds; non-Hispanic Black or African Americans; those with anxiety or depression; physically inactive; overweight or a heart condition; or lived in a food-insecure or smoking household.
Dr. Jack Cush reviews the news and journal reports and this week, takes on 5 cases/questions from "Ask Cush Anything"
Dr. John Cush RheumNow
3 years 3 months ago
Study of >19K RA pts in National Databank showed that Opioids vs NSAID use had similar MACE risk(20.6 vs 18.9/1000 PY), but opioids had higher mortality (13.5 vs 10.8/1000 PY; HR1.33) & VTE risk(HR=1.41). Opioids are not safer than NSAIDs https://t.co/J56BqYMKM1 https://t.co/xiz4GGUnJC
Dr. John Cush RheumNow
3 years 3 months ago
BE OPTIMAL study: Bimekizumab vs adalumumab in 702 #PsA pts, showed sustained 52 week ACR50 responses at wk 52: 54% BKZ v 50% ADA; PASI 100 61% BKZ v 48% ADA. Serious AE seen in 6.6% of BKZ patients, 1 death and 7.7% w/ Candida (vs 0.7% w/ ADA) https://t.co/4g3j5OoKyy https://t.co/g4SQubSCXg
Tofacitinib is FDA approved for psoriatic arthritis and rheumatoid arthritis, but long term safety outcomes beyond a year are limited. A real-world, post-marketing surveillance of tofacitinib in PsA and RA shows a consistent pattern of safety with no new safety concerns identified.
Dr. John Cush RheumNow
3 years 3 months ago
JAMA has a review of "Diagnosis and Treatment of Hip and Knee Osteoarthritis".
Affecting 240 million people worldwide, >32 million in the US. OA Risk factors include age, female, obesity, genetics, & trauma/injury. OA pts have more comorbidities https://t.co/ee10MKIqUp https://t.co/N2i3VWgvc9
